首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   19582篇
  免费   1477篇
  国内免费   536篇
耳鼻咽喉   98篇
儿科学   190篇
妇产科学   330篇
基础医学   1588篇
口腔科学   246篇
临床医学   1520篇
内科学   4309篇
皮肤病学   305篇
神经病学   959篇
特种医学   227篇
外国民族医学   1篇
外科学   1833篇
综合类   1263篇
预防医学   347篇
眼科学   241篇
药学   4775篇
  6篇
中国医学   262篇
肿瘤学   3095篇
  2023年   425篇
  2022年   522篇
  2021年   739篇
  2020年   841篇
  2019年   733篇
  2018年   664篇
  2017年   795篇
  2016年   742篇
  2015年   816篇
  2014年   1135篇
  2013年   2324篇
  2012年   936篇
  2011年   1180篇
  2010年   881篇
  2009年   979篇
  2008年   1027篇
  2007年   947篇
  2006年   938篇
  2005年   757篇
  2004年   622篇
  2003年   537篇
  2002年   438篇
  2001年   354篇
  2000年   268篇
  1999年   216篇
  1998年   202篇
  1997年   163篇
  1996年   142篇
  1995年   141篇
  1994年   121篇
  1993年   106篇
  1992年   95篇
  1991年   85篇
  1990年   75篇
  1989年   75篇
  1988年   54篇
  1987年   66篇
  1986年   41篇
  1985年   63篇
  1984年   57篇
  1983年   38篇
  1982年   51篇
  1981年   33篇
  1980年   33篇
  1979年   34篇
  1978年   32篇
  1977年   19篇
  1976年   18篇
  1975年   9篇
  1973年   9篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
AimThis review aims to summarize and discuss some of the most relevant clinical trials in epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021.Data synthesisThe trials included in this review are related to hypertension onset age and risk for future cardiovascular disease, reliability of different blood pressure monitoring methods, role of exercise-induced hypertension, treatment of hypertension in patients with SARS-CoV-2 infection, management of hypertension high-risk patient groups, e.g., in the elderly (≥80 years) and patients with atrial fibrillation, and the interplay between nutrition and hypertension, as well as recent insights into renal denervation for treatment of hypertension.ConclusionsHypertension onset age, nighttime blood pressure levels and a riser pattern are relevant for the prognosis of future cardiovascular diseases. The risk of coronary heart disease appears to increase linearly with increasing exercise systolic blood pressure. Renin-angiotensin system blockers are not associated with an increased risk for a severe course of COVID-19. In elderly patients, a risk-benefit assessment of intensified blood pressure control should be individually evaluated. A J-shaped association between cardiovascular disease and achieved blood pressure could also be demonstrated in patients with atrial fibrillation on anticoagulation. Salt restriction and lifestyle modification remain effective options in treating hypertensive patients at low cardiovascular risk. Sodium glucose co-transporter 2 inhibitors and Glucagon-like peptide-1 receptor agonists show BP-lowering effects. Renal denervation should be considered as an additional or alternative treatment option in selected patients with uncontrolled hypertension.  相似文献   
2.
成纤维细胞生长因子受体(FGFR)信号的异常在多种肿瘤中被发现,FGFR信号的异常参与了肿瘤发生的多项进程,包括细胞存活、增殖、炎性反应、迁移、血管生成、上皮间质转化及耐药。故FGFR是治疗肿瘤有应用前景的靶点,越来越多的FGFR抑制剂进入临床前研究及临床研究阶段,部分FGFR抑制剂已被批准应用于临床。但是获得性耐药及全身毒性等问题阻碍了FGFR抑制剂的应用。本文综述了常见FGFR抑制剂的临床应用并对其中出现的问题及解决措施作一总结。  相似文献   
3.
4.
Ying Fu  Simo Liu  Yan Ma  Nannan Wu 《中国药学》2022,31(8):569-588
Canagliflozin (CANA) is a sodium-glucose co-transporter 2 inhibitor. One of the important mechanisms of CANA is the inhibitory effect on the glucose uptake in the proximal tubule of the nephron, and the other mechanism can be the reduction of inflammatory cytokine expression monocytes and macrophages. It is proved by FDA for the management of type 2 diabetes. In the present work, we summarized the publication and clinical evidence of the CANA on healthy individuals and those with related metabolic diseases, such as type 1 and 2 diabetes, obesity, or cardiovascular and kidney diseases. This drug has been reported to offer potential advantages in regulating body weight and reducing heart failure, hypoglycemia, and stroke risk in patients with type 2 diabetes. Some in vitro and animal experiments also show that this drug has good effects on cancer treatment. However, some case reports and experiments also show the side effect of CANA, such as amputation, fracture, and pancreatitis, while the mechanism is still unknown. Overall, CANA has a good effect on the management of type 2 diabetes by reducing the risk of kidney failure, cardiovascular diseases, and stroke. However, as a new drug, more clinical trials and experiments of CANA should be carried out in the future.  相似文献   
5.
子宫浆液性癌(uterine serous carcinoma,USC)是一种特殊类型的子宫内膜癌。有别于常见的子宫内膜样腺癌,USC较为少见,且恶性程度高,侵袭转移风险高,临床上预后较差。随着子宫内膜癌分子学研究的不断深入,分子学特征被应用于子宫内膜癌的病理分型诊断、治疗和预后评价中。研究发现USC中存在多种基因的突变,这些相关基因的突变对该病的诊断和预后具有重要的指导意义。同时,特异性的分子学改变为USC的靶向治疗提供了潜在的治疗靶点。目前,多种靶向治疗手段包括人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)抑制剂、免疫检查点抑制剂、抗血管生成治疗、磷脂酰肌醇3激酶(phosphoinositide 3-kinases,PI3K)通路抑制剂和多腺苷二磷酸核糖聚合酶[poly(ADP-ribose) polymerase,PARP]抑制剂等被应用于USC的临床治疗研究中,针对性的靶向治疗有望成为USC治疗的新突破。  相似文献   
6.
7.
8.
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with intermediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozantinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号